Home
You need to upgrade your Flash Player to version 8 
 
Home
UI Research
BioVentures Center
Technology Innovation Center
Technology Transfer
IOWA Centers for Enterprise
Available Land & Buildings
News & Events
Download Center
Contact Us



KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD
North Liberty, IA -- October 22, 2009 – KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
Read more...
UI student business wins $50,000 federal grant to develop biomass for energy
A University of Iowa-based student business has received a $50,000 federal grant to help develop a system of helping farmers transport biomass to utilities, large industries and biofuel companies for conversion to electricity.
Read more...
UI Pharmaceuticals passes FDA inspection
In September 2009, the Kansas City District Office of the Food and Drug Administration (FDA) submitted a recommendation of approval to the Center for Drug Evaluation and Research for The University of Iowa Pharmaceuticals (UIP) to manufacture and test an aseptically filled, sterile prescription drug product for a commercial client. The drug product contains a new chemical entity and is a sterile solution that is aseptically filled into vials.
Read more...